untitled

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "untitled"

Transcription

1 MACS Cytokines product list MACS Miltenyi Biotec Nature ES/iPS MACS Research grade Premium grade ex vivo GMP grade MACS WEB

2 HUMAN Cytokines and Growth Factors HumanKine Re HEK293 5 μg 25, Activin A 50 μg 124, μg 477, ANGPTL5 Re HEK293 5 μg 27, μg 103, BAFF (TNFSF13B, BLys) BD-2 Re E. coli BD BDNF Re E. coli 2 μg 11, μg 165, μg BMP-2 Re E. coli 2 μg 11, μg 165, HumanKine Re HEK μg 32, BMP-4 50 μg 124, μg 435, BMP-7 Re CHO μg 249, CD40-Ligand Pr E. coli 10 μg 25, soluble (TRAP, CD154, TNFSF5) 25 μg 37, μg 103, μg CD40-Ligand Pr E. coli 100 μg 165, Multimer kit μg CD137-Ligand (4-1BB-Ligand) CNTF DKK-1 Re HEK293 2 μg 11, μg 165, EGF Re E. coli 100 μg 11, Pr E. coli 100 μg 14, μg μg EG-VEGF Re E. coli (Prokineticin 1) Exodus (CCL21, SLC) FGF (acidic FGF, afgf, HBGF-1) 25 μg 22, Pr E. coli 10 μg 14, μg 28, μg 50, μg (basic FGF, bfgf,hbgf-2) μg 25, Pr E. coli 10 μg 14, μg 37, μg 50, μg 82, μg μg IS Re E. coli 10 μg 14,000 (improved sequence) (basic FGF, bfgf) μg 37, Pr E. coli 10 μg 20, μg 52, μg 103, μg FGF-4 (HBGF-4) Re E. coli 25 μg 37, FGF-7 (KGF, HBGF-7) μg 57, Pr E. coli μg 72, μg 165, FGF-8b Re E. coli 10 μg 20, μg 30, Pr E. coli 10 μg 25, μg 37, μg 103, μg FGF μg 61, FGF-10 (KGF-2) Re E. coli 25 μg 37, FGF μg 37, μg 37, Flt3-Ligand μg 57, Pr E. coli μg 72, μg 124, μg Galectin-1 Re E. coli 50 μg 37, Galectin-3 Re E. coli 50 μg 37, G-CSF μg 57, Pr E. coli μg 72, μg 165, μg GDF GDNF Re E. coli 2 μg 11, μg 165,200 2

3 Re E. coli 10 μg 20,000 (CSF2) μg 46, Pr E. coli 10 μg 25, μg 57, μg 103, μg μg GRO-α (CXCL1, MGSAα) μg 37, GRO-β (CXCL2, Re E. coli 2 μg 11,000 MGSAβ, MIP-2α) HGF 2 Re Insect 5 μg 20, (HPTA, SF) 25 μg 72, μg 165, IFN-α2a Re E. coli 20 μg 11, μg 37, IFN-α2b Re E. coli 20 μg 11, μg 37, IFN-β1a Re CHO 5 μg 11, IFN-β1b Re E. coli 2 μg 11, IFN-γ1b (IFN-γ) μg 16, Pr E. coli 10 μg 14, μg 20, μg 41, μg IGF-1 Re E. coli 50 μg 28,000 (IGF-I) μg 37, μg IGF-2 (IGF-II) μg 37, μg IL-1α Re E. coli 2 μg 11, IL-1β (IL1F2) μg 57, Pr E. coli μg 72, μg 124, μg IL-1ra Re E. coli 20 μg 11, IL-2 IS (improved sequence) μg 30, Pr E. coli 10 μg 14, μg 37, μg 61, μg Re E. coli 10 μg 26, μg 41, x 25μg 103, Pr E. coli 10 μg 32, μg 52, μg 103, μg Re E. coli 5 μg 13, μg 20, μg 41, μg 82, Pr E. coli 5 μg 17, μg 25, μg 52, μg 103, μg IL-5 Re E. coli 2 μg 11, IL-6 Re E. coli 10 μg 26, μg 41, Pr E. coli 10 μg 32, μg 52, μg 103, μg μg IL μg 57, Pr E. coli μg 72, μg 165, μg IL-8 (72 aa) (CXCL8) μg 37, IL-8 (77 aa) (CXCL8) Re E. coli 25 μg 37, IL-9 Re E. coli 2 μg 11, μg 165, IL-10 Re E. coli 2 μg 11, μg 165, IL-11 Re E. coli 2 μg 11, μg 165, IL-12 Pr HEK293 5 μg 25, μg 78, μg 249, IL-13 Re E. coli 2 μg 11, μg 165,200 Re : Research Pr : Premium ( ) 3

4 HUMAN Cytokines and Growth Factors IL μg 57, Pr E. coli μg 72, μg 124, μg IL-15Rα sushi μg 22, Pr E. coli 10 μg 14, μg 28, μg 61, IL-17A μg 37, μg 124, IL-17F μg 37, IL-19 Re E. coli 2 μg 11, IL μg 57, Pr E. coli μg 72, μg 165, IL-22 Re E. coli 2 μg 11, μg 165, IL-23 Re HEK293 5 μg 27, μg 103, μg 332, IL-24 Re CHO 5 μg 11, Re E. coli 2 μg 11, Re HEK293 2 μg 11, LIF μg 37, μg 138, μg MCP (CCL2, MCAF) M-CSF (CSF1) 25 μg 57, Pr E. coli μg 72, μg 124, μg MIP-3α Re E. coli (CCL20, Exodus-1) MIP-3β (CCL19, ELC, Exodus-3) 25 μg 37, μg 124, NGF-β Re CHO 5 μg 20, (β-ngf) 20 μg 41, μg 103, Noggin Re HEK293 5 μg 11, μg 124, NT-3 Re E. coli 2 μg 11, (NTF-3, HDNF) μg 165, NT-4 Re E. coli 2 μg 11, (NTF-4) Oncostatin M (OSM) Re E. coli 2 μg 11, μg 165, μg OPG Re Yeast 50 μg 37,000 (TNFRSF11B, TR1) PDGF-AA Re E. coli 2 μg 11, PDGF-AB Re E. coli 2 μg 11, μg 124, PDGF-BB IS Re Yeast 10 μg 26, (improved sequence) 25 μg 41, Pr Yeast 10 μg 32, μg 52, μg 103, μg Prolactin Re E. coli 50 μg 37,000 (Mammotropin) RANK-Ligand Re E. coli 2 μg 11, soluble (TNFSF11, TRANCE, ODF) μg 165, RANTES (CCL5) R-Spondin -1 Re CHO 5 μg 11, (Rspo-1, F-spondin) R-Spondin -2 Re CHO 5 μg 11, (Rspo-2) R-Spondin -3 Re CHO 5 μg 11, (Rspo-3) SCF Re E. coli 10 μg 26, (c-kit Ligand, steel factor, MGF) 25 μg 41, Pr E. coli 10 μg 32, μg 52, μg 103, μg SDF-1α Re E. coli 10 μg 32, (CXCL12) 25 μg 52, μg 103, μg SHH (C24II) Re E. coli 10 μg 26, μg 41, Pr E. coli 10 μg 32, μg 52, μg 103, μg TARC (CCL17) Re E. coli 4

5 MOUSE Cytokines and Growth Factors TGF-β1 Pr HEK293 5 μg 50, μg 110, TGF-β3 3 Re E. coli 5 μg 27, μg 103, TNF-α Re Yeast 10 μg 11, (TNFSF2) 50 μg 30, μg 49, μg μg Pr Yeast 10 μg 14, μg 37, μg 61, μg Pr E. coli 10 μg 14, TPO (MDGF) 100 μg 145, TRAIL (Apo2 Ligand, TNFSF10) 50 μg 37, TSLP Re E. coli 2 μg 11, VEGF (121 aa) 2 Re Insect 5 μg 41, μg 165, VEGF (165 aa) 2 Re Insect 5 μg 41, μg 73, μg 239, μg 1 Cross link 2-8 C C EGF Re E. coli 100 μg 11, μg (basic FGF, bfgf, HBGF-2) μg 37, FGF-8b Re E. coli 10 μg 20, μg 30, Pr E. coli 10 μg 25, μg 37, μg 103, μg Flt3-Ligand Re E. coli μg 124, G-CSF Re E. coli 2 μg 11, μg 165, Re E. coli 10 μg 26,000 (CSF2) μg 41, Pr E. coli 10 μg 32, μg 52, μg 103, μg Gro-α/KC (CXCL1) IFN-α 1 Re HEK μl 61, ml IFN-γ Re E. coli 20 μg 11, μg 37, μg IL-1α Re E. coli 2 μg 11, IL-1β (IL1F2) μg 57, Pr E. coli μg 72, μg 165, μg IL μg 103, IS (improved sequence) μg 57, Pr E. coli μg 72, μg 124, μg Re E. coli 10 μg 26, μg 41, Pr E. coli 10 μg 32, μg 52, μg 103, μg IL μg 37,000 Re : Research Pr : Premium ( ) 5

6 MOUSE Cytokines and Growth Factors IL μg 57, Pr E. coli μg 72, μg 124, μg IL-7 Re E. coli 2 μg 11, μg 165, IL-10 Re E. coli 2 μg 11, IL-12 Re HEK293 5 μg 25, μg 78, μg 249, IL-13 Re E. coli 2 μg 11, IL-15 Re E. coli 2 μg 11, μg 165, IL-17A μg 37, IL-17F μg 37, IL-22 Re E. coli 2 μg 11, IL-23 Re HEK293 5 μg 27, μg 103, IP-10 (CXCL10) μg 37, LIF μg 57, Pr E. coli μg 72, μg 124, x100 μg M-CSF (CSF1) μg 57, Pr E. coli μg 72, μg 124, μg MIG (CXCL9) MIP-3β (CCL19, ELC, Exodus-3) μg 124, Noggin μg 30, μg 124, RANK-Ligand Re E. coli 2 μg 11, soluble (TNFSF11) μg 165, RANTES (CCL5) Re E. coli SCF Re E. coli 10 μg 26, (c-kit Ligand, steel factor, MGF) 25 μg 41, Pr E. coli 10 μg 32, μg 52, μg 103, μg SDF-1α Re E. coli 2 μg 11, (CXCL12) TNF-α Re E. coli 10 μg 26, (TNFSF2) 25 μg 41, Pr E. coli 10 μg 32, μg 52, μg 103, μg TPO Re E. coli 2 μg 11, (MDGF) μg 165, VEGF Re Insect 5 μg 31, (164 aa) 2 20 μg 73, C 2 RAT Cytokines and Growth Factors IFN-γ Re E. coli 100 μg 37, IL Re E. coli 2 μg 11, VEGF-C 1 Re Insect VEGF-C (C152S) 1 Re Insect 5 μg 31, Re : Research Pr : Premium ( )

7 MACS NeuroBrew-21 & NeuroMedium B27MACS NeuroBrew-21 MACS Neuro Medium CNS PNS MBP MACS Neuro Medium + MACS NeuroBrew-21+ L-glutamine PDGF-AA, PSA-NCAM MicroBeads MACS NeuroBrew-21 MACS Neuro Medium 7 GAD MACS Neuro Medium (,, ) 500 ml 6, MACS NeuroBrew-21 (50x) 10 ml 18, MACS NeuroBrew-21 (50x, Vitamin A) 10 ml 18, C GMP GMP/GCTP TR translational research (ex vivo) GMP HUMAN GMP HUMAN EGF GMP E. coli 100 μg 110, μg 340, GMP E. coli 25 μg 80,000 (basicfgf, bfgf) μg 400, Flt3-Ligand GMP E. coli 100 μg 340, GMP E. coli 25 μg 80, μg 320, IL-1β GMP E. coli 25 μg 110, IL-2 GMP E. coli 20 μg 38, μg 95, μg coming soon GMP E. coli 25 μg 80, GMP E. coli 25 μg 110, μg 320, IL-6 GMP E. coli 10 μg 50, IL-7 GMP E. coli 25 μg 110, IL-15 GMP E. coli 25 μg 110, IL-21 GMP E. coli 25 μg 110, SCF GMP E. coli 100 μg 340, TNF-α GMP E. coli 25 μg 80,000 TPO GMP E. coli 50 μg coming soon GMP : GMP 7

8 MACS MACS TexMACS T T TregT HSA RPMI %FCS T GMPPR(phenol red) T TexMACS 2-8 C TexMACS Medium, research grade 500 ml 12, TexMACS GMP medium 1 L 18, TexMACS GMP medium(pr) 1 L 18, TexMACS GMP medium(pr) 2 L 36,000 TexMACS GMP grade TexMACS reseach grade RPMI + 10% FCS Expansion rate (x10 n ) CD3 + CD4 + CD8 + TexMACS Medium 10%FCS+RPMI T TexMACS Medium FCS RPMI CD4 + T CD8 + T CytoBox CytoBox Cytobox Mo-DC() Mo-DCs monocyte-derived dendritic Premium grade Cytobox Anti-IFN-γ-APC CytoBox Th1 Anti-IFN-γ-APC / Anti--PE Anti-T-bet-PE CytoBox Mo-DC 1 406,400 CytoBox Th2 Cytobox Th( ) CD4 + T in vitro polarization Th1 Th2 Th17 TexMACS Medium T cell Activation/Expansion Kit Anti-IFN-γ-APC Anti--PE Anti-T-bet-PE Anti-GATA3-APC Cytobox Th( ) / 2-8 C / CytoBox Th1 IL-12 IL-2 Anti CytoBox Th2 IL-2 Anti-IFN-γ 1 59, ,100 Anti-IFN-γ-APC CytoBox Th17 Anti-RORγ (t)-apc Anti-IL-17A-PE Anti-IL-17A-PE CytoBox Th17 IL-6, TGF-β, IL-1β, IL-23 Anti-IFN-γ,, IL ,200 CD4 + in vitro polarization TexMACS Medium, 10% FCS, T cell Activation/Expansion Kit (# ) CytoBox 5 Intracellular staining Th lineage 8

9 Helper T Naive CD4 T cell IL-2 Anti-CD3 Anti-CD28 IL-12 IL-18 IL-27 IFN-γ Anti- IL-6 1 IL-23 TSLP IL-25 Anti-IL-12 Anti-IFN-γ TGF-β1 Anti-IFN-γ TGF-β1 TGF-β1 IL-1β IL-6 IL-21 IL-23 Anti-IL-2 Anti- Anti-IFN-γ IL-6 IL-21 CXCL13 IL-6 TNF-α TH1 cell TH2 cell TH9 cell itreg cell TH17 cell Tfh cell TH22 cell CD4, CD94, CD119 (IFN-γ), CD183 (CXCR3), CD195 (CCR5), Tim-3 CD4, CD119 (IFN-γ), CD193 (CCR3), CD194 (CCR4), Tim-1 CD4, TCRα/β CD196 (CCR6) CD4, CD25, CD127 - CD4, CD161, CD194 (CCR4), CD196 (CCR6) CD4, TCRα/β, CD185 (CXCR5), CD197 (CCR7), CD69 CD4, CD194 (CCR4), CD196 (CCR6), CCR10 T-bet, STAT1, STAT4 GATA3, STAT6 IRF4, GATA3, STAT6 FoxP3, STAT5, Smad2 RORγt, STAT3 STAT3, Bcl6 BNC2, FOXO4 IL-2, IL-10, IFN-γ, TNF-α,, IL-5, IL-6, IL-10, IL-13 IL-9, IL-10 IL-10, TGF-β1, 5 IL-17A, IL-17F, IL-21, IL-22, IL-26 IL-6, IL-10, IL-12, IL-21 IL-13, IL-22, TNF-α Polarizing cytokines Surface marker profile Transcription factors Secreting cytokines Blocking or neutralizing antibodies Activating antibodies in vivo Azide-free in vitro in vivo (1mg~) (9:00-17:00) 2-8 C CD3 pure() 100 μg 35, CD28 pure() 100 μg 35, CD335 (NKp46) pure() 100 μg 45, Anti-iNKT pure () 100 μg 45, Anti-IFNγ pure () 500 μg 64, Anti- pure () 500 μg 64, Anti-IL-12 (p40/p70)pure () 500 μg 68, CD357 (GITR)pure () 500 μg 98, CD279 (PD-1) pure () 500 μg 68,000 WEB B cell Expansion Kit () B / 2-8 C B / B cell Expansion Kit CD40-Ligand, Cross-Link StemMACS HSC Expansion Media XF 1 890,000 : 9

10 StemMACS TM mrna, StemMACS StemMACS ips-brew XF(xeno-free media) ES/iPS Feeder-Free Xeno-Free On-Feeder Feeder-Free StemMACS MSC Expansion Media Kit XF Xeno-Free MSCs ( ) StemMACS ips-brew XF 20 ips ( ) StemMACS mrna Reprogramming Kit ips StemMACS HSC Expansion Media XF Xeno-Free StemMACS HSC Expansion Cocktail StemMACS ips-brew XF ips NOD-Scid 8 3 StemMACS ips StemMACS ips-brew XF () *1 500 ml + 5 ml 29, StemMACS Passaging Solution XF *2 100 ml 7,500 (MSCs) StemMACS MSC Expansion Media Kit XF () *1 500 ml + 7 ml 59, StemMACS HSC Expansion Media XF ( ) 100 ml 20,000 (HSCs) StemMACS HSC Expansion Media XF ( ) 500 ml 65, StemMACS HSC Expansion Cocktail () ml 98,000 *12-8 C*2 : StemMACS small molecule CHIR99021 Wnt GSK3β PD MEK A83-01 TGF-β, Activin Nodal SB TGF-β, Activin Nodal Dorsomorphin BMP AMP Purmorphamine IWP-2 β Wnt LDN BMP type I ALK2 ALK3 Thiazovivin Rho-associated kinase (ROCK) LY Notchγ RG108 DNA methyltransferase (DNMT) StemMACS mrna & StemMACS mrna Reprogramming Kit Feeder-Free mrna Conditioned medium 2 StemMACS mrna Transfection Kit mrna StemMACS Repro-Brew XF mrna PPAR-gamma, C/EBP-beta Brn2, Lmx1a, Mash1, NeuroD1, NeuroG2, Nurr1, Myt1l Progerin-eGFP Nuclear egfp, egfp Flp Recombinase, Cre Recombinase Cas9 Nickase, Cas9 Nuclease 10

11 PSCs /, TGF-β1, Thiazovivin, Y27632 ips/es Activin A CHIR99021 Pluripotent stem cell (ESC/iPSC) FGFs, Noggin, SB431542, Dorsomorphin, LDN BMP-4 Ascorbic acid Definitive endoderm Keratinocyte Neural stem cell A83-01 Dorsomorphin Noggin Wnt3a FGF-4 FGF-10 Retinoid acid SB Retinoid acid Noggin FGF-7 BMP-4 EGF VEGF Dorsomorphin SHH FGF-8b SHH CNTF SHH PDGF Retinoid acid EGF Anterior endoderm BMP-4 WNTs Hindgut endoderm R-Spondins EGF Noggin Hepatic progenitor HGF FGF-4 EGF Pancreatic progenitor Exendin-4 BMP-4 Nicotinamide Multipotent endodermal progenitor cell Neural Crest NGF BDNF GABA neuron Dopaminergic neuron Astrocyte Oligodendrocyte Cortical neuron Multipotent lung progenitor Intestinal tissue Hepatocyte β-islet cell Insulin, Transferrin, Selenium, Serum Peripheral neuron BMP-4, Activin-A,, CHIR99021 Insulin IBMX Dexamethasone Mesenchymal stem cell Dexamethasone TGF-β1 TGF-β3 Ascorbic acid SCF, TPO Flt3-L IL-6, G-CSF BMP-4, VEGF SCF, TPO, Flt3L Primitive streak mesoderm XAV939 KY02111 DKK-1 IWP-2 VEGF SB Adipocyte Osteogenic cell Chondrocyte Hematopoietic stem cell Cardiomyocyte Endothelial cell SCF IL-7 SCF TPO, IL-6, G-CSF,, EPO Lymphoid progenitor Megakaryocyte erythrocyte progenitor Common myeloid progenitor SCF, IL-1β IL-6, IL-7 IL-11, IL-12 SCF IL-2 IL-12 SCF, IL-1β IL-2, IL-6 IL-7 TPO EPO M-CSF IL-10 TSLP IL-5 G-CSF SCF TGF-β1 B cell lineage TGF-β1, BAFF IL-2, IFN-γ, CD40L anti CD40 anti CD180 anti IgM/IgD NK cell lineage IL-2 IL-12 IL-15 IL-18 T cell lineage IL-2 IL-7 IL-15 CD137L anti CD3 anti CD28 Megakaryocyte lineage Erythroid lineage M-CSF RANK-L Monocytic lineage Flt3L M-CSF 4 Basophilic lineage IFN-γ Flt3L 4 Eosinophilic lineage Neutrophilic lineage Mast cell lineage Activated B cell Activated NK cell Osteoclast Macrophage TNF-α, IFN-γ, IL-1β IL-13 Dendritic cell IL-1β, TNF-α IL-6, IL-23 CD40L Plasma cell NK T cell γδ T cell CD4 naive T cell CD8 naive T cell Treg cell Mature macrophage Mature dendritic cell StemMACS MACS Activating antibodies 11

12 MACS Research grade 1 Research grade 0.1 ng/μg(1 EU/μg) 95% 1 WHO NIBSC 2 Carrier 2 Carrier-freetrehalose, mannitolstabilizer premium grade / 2 Mouse LIF (premium grade) ES WEB GMP gradeex vivo GMP ISO 9001:2000 MACS GMP USP( )<1043> ancillary materials MACS Miltenyi Biotec GmbH Miltenyi Biotec NEX5F TEL FAX AM9 00 PM dE800

LEGENDplex の特長 LEGENDplex は 一つのサンプルから多の可溶性タンパクを同時に定量できるフローサイトメーター用ビーズアッセイキットです 最大 13 まで同時測定が可能 Pre-defined Panel Mix & Match からキットを選べます 1 Pre-defined

LEGENDplex の特長 LEGENDplex は 一つのサンプルから多の可溶性タンパクを同時に定量できるフローサイトメーター用ビーズアッセイキットです 最大 13 まで同時測定が可能 Pre-defined Panel Mix & Match からキットを選べます 1 Pre-defined フローサイトメーターによる多タンパク同時定量解析キット BioLegend is ISO 9001:2008 and ISO 13485:2003 Certified World-Class Quality Superior Customer Support Outstanding Value 02-0009-02j LEGENDplex の特長 LEGENDplex は 一つのサンプルから多の可溶性タンパクを同時に定量できるフローサイトメーター用ビーズアッセイキットです

More information

第14〜15回 T細胞を介する免疫系.pptx

第14〜15回 T細胞を介する免疫系.pptx MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α

More information

研修コーナー

研修コーナー l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l

More information

19 8 1970 20 10 4 1

19 8 1970 20 10 4 1 19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE

More information

9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00

9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00 9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00 ポスターについて 1. ポスター 貼 付 用 の 展 示 ボードは 縦 180 横 90cm の 大 きさです 2. 演 題 名 発 表 者 名 所 属 を 明 記 したもの(20 70cm) をご 用 意 ください 実 際 使 用 できるスペースは 155

More information

jcvp試験問題HP.indd

jcvp試験問題HP.indd 22 18 JCVP 1 G a e 1 G 1. A. B. C. D. P450 E. SOD c G 2. A. B. C. mrna D. E. G 3. G 4. A. B. ATP C. D. E. a A. B. C. 25 nm D. 10 nm E. 4 6 nm c d G 5. G 6. G 7. A. B. SOD C. D. E α E. d a. b. c. d. e.

More information

第86回日本感染症学会総会学術集会後抄録(I)

第86回日本感染症学会総会学術集会後抄録(I) κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β

More information

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35

More information

DiovNT

DiovNT Peptide Antisera and Monoclonal Antibodies (2) Antisera of Yanaihara Institute Inc. Monoclonal Antibodies Peptide Antisera and Antisera of Yanaihara Institute Inc. 274 Manufacturer: YANAIHARA INSTITUTE

More information

1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e

1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e No. 1 1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e I X e Cs Ba F Ra Hf Ta W Re Os I Rf Db Sg Bh

More information

日本歯科保存学会2011年度春季学術大会(134回)

日本歯科保存学会2011年度春季学術大会(134回) ii 2011 134 Program and Abstracts, the 134th Meeting of the Japanese Society of Conservative Dentistry, June 910, 2011, Chiba A 1F B 1F 2 1F 6 9 A112 B112 P160 6 10 A1319 B1319 P61114 A2028 B2028 6 910

More information

第124回日本医学会シンポジウム

第124回日本医学会シンポジウム III γ γ γ α γ Molecular Mechanism of Insulin Resistance by Adipocytes TAKASHI KADOWAKI Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo Key words γ 110 124 TNFα FFA 1,2

More information

nsg04-28/ky208684356100043077

nsg04-28/ky208684356100043077 δ!!! μ μ μ γ UBE3A Ube3a Ube3a δ !!!! α α α α α α α α α α μ μ α β α β β !!!!!!!! μ! Suncus murinus μ Ω! π μ Ω in vivo! μ μ μ!!! ! in situ! in vivo δ δ !!!!!!!!!! ! in vivo Orexin-Arch Orexin-Arch !!

More information

5 ex. neo^r ex. P. ips induced Pluripotent Stem cells 4 ES ex. ex. DNA

5 ex. neo^r ex. P. ips induced Pluripotent Stem cells 4 ES ex. ex. DNA 4 MZ DZ MZ DZ ex.mz 0.8 DZ 0.4 2 ex. 0.8 ex. MZ 0.8 DZ 0.6 ex. MZ 0.8 DZ 0.1 E LDL E2 E3 E4 128 152 E2 CC E3 CR E4 RR 10 ex. G6PD CYP CYP P CYP CYP CYP3 CYP CYP 5 ex. neo^r ex. P. ips induced Pluripotent

More information

免疫Ⅱ

免疫Ⅱ 100 100 100 1990 127 DNA DNA DNA DNA hybridization DNA RNA DNA DNA 128 12 µδγαε 129 300 1,200 500 50012 4 24,000 1,20024,000 2.910 7 10 8 rejection major histocompatibility complex MHC MHC MHC 130 MHC

More information

nsg02-13/ky045059301600033210

nsg02-13/ky045059301600033210 φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W

More information

150903_Corning Cell Culture Surfaces.indd

150903_Corning Cell Culture Surfaces.indd Corning Cell Culture Surfaces ....................................................... 1.................................................. 2 Corning.................. 2 Corning BioCoat....................................................

More information

内科96巻3号★/NAI3‐1(第22回試験問題)

内科96巻3号★/NAI3‐1(第22回試験問題) µ µ α µ µ µ µ µ µ β β α γ µ Enterococcus faecalis Escherichia coli Legionella pneumophila Pseudomonas aeruginosa Streptococcus viridans α β 正解表正解記号問題 No. 正解記号問題 No. e(4.5) 26 e 1 a(1.2) 27 a 2

More information

日本医科大学医学会雑誌第8巻第1号

日本医科大学医学会雑誌第8巻第1号 Xenopus laevis in situ μ μ Xenopus laevis Xenopus laevis Xenopus laevis UGT1A1 UGT1A1 IL28B KRAS UGT1A1 UGT1A128 UGT UGT1A1 UGT1A128 UGT1A1 286 UGT1A1 UGT1A1 28 6 UGT UGT UGT1A128 UGT IL28B UGT1A1

More information

OCT 101 BSA Tris buttered saline TBS 1 p75ntr 1:100 CD90 1:100CD105 1:100 CD146 1:100PDGF PDGFR, 1:100 1:100von Willebrand factor vw

OCT 101 BSA Tris buttered saline TBS 1 p75ntr 1:100 CD90 1:100CD105 1:100 CD146 1:100PDGF PDGFR, 1:100 1:100von Willebrand factor vw Vol.1 2013 pp.1-7 1 2 1 1 1 3 4 5 Development of novel cell therapies using stem cells in umbilical cord blood and cord tissue Hideo MUGISHIMA 1 Taro MATSUMOTO 2 Hiroshi YAGASAKI 1 Mika ISHIGE 1 Sumiko

More information

Gallios_1312.indd

Gallios_1312.indd TM Gallios Gallios 4 Laser System Powerful Versatile Performance Fast Track to Success CE9904 2013.12-2000E Gallios High End Flow Cytometer 1 2 Accuracy 60 50 40 30 20 10 0-10 Log Decade Display Gallios

More information

日歯雑誌(H28・8月号)別刷り/ポスターセッション とびら

日歯雑誌(H28・8月号)別刷り/ポスターセッション とびら α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α

More information

PX-047A Series

PX-047A Series B K L & L & A B C D E F A B A B C A B C A B A B A B C D E F G P BB H I y y & & K L L & & K L L L L & & & & L d L & & & & L L & & & L & & & & L & & & & & & & & L L L L L L & & & A B C D E F G

More information

<4D6963726F736F667420506F776572506F696E74202D20328D528EEEE18796C68975899E939A82F09798977082B582BD82AA82F196C689758EA197C38DEC97708B408F988169967B8BB4905688EA9859298DC58F495B93C782DD8EE682E890EA97705D>

<4D6963726F736F667420506F776572506F696E74202D20328D528EEEE18796C68975899E939A82F09798977082B582BD82AA82F196C689758EA197C38DEC97708B408F988169967B8BB4905688EA9859298DC58F495B93C782DD8EE682E890EA97705D> 抗 腫 瘍 免 疫 応 答 を 利 用 したがん 免 疫 治 療 の 作 用 機 序 千 葉 大 学 大 学 院 医 学 研 究 院 免 疫 細 胞 医 学 本 橋 新 一 郎 2016 年 6 月 17 日 第 26 回 がん 臨 床 研 究 フォーラム 研 究 費 の 財 源 受 託 寄 付 科 学 研 究 費 その 他 ( ) 財 源 の 供 給 元 文 部 科 学 省 厚 生 労 働 省 AMED

More information

報告書

報告書 1 2 3 4 5 6 7 or 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2.65 2.45 2.31 2.30 2.29 1.95 1.79 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 60 55 60 75 25 23 6064 65 60 1015

More information

A I (MHC-I; HLA-A, B, C H-2K, D, L ) II (MHC-II; HLA-DR, DQ, DP I-A, I-E ) CHO CHO m CHO CHO CHO B MHCI MHCII MHC-I MHC-II B (APC) T α β2 α α1, α2 α3 α β α β α1, α2, β1 β α1α2 ΙΙ α1β1 3 B B CD4 TCR MHC-II

More information

PAXgene Tissue DNA Kitプロトコールとトラブルシューティング(2301605 06/2009)

PAXgene Tissue DNA Kitプロトコールとトラブルシューティング(2301605 06/2009) January 2009 PAXgene Tissue DNA Kit PAXgene Tissue Containers DNA PAXgene Tissue Container PAXgene DNA 3 PAXgene DNA 6 PAXgene DNA 9 13 2 PAXgene Tissue DNA Kit 01/2009 PAXgene DNA DNA PAXgene Tissue Containers

More information

2

2 27 年 度 精 神 保 健 福 祉 基 礎 研 修 会 1 2 350 300 303 323 250 200 150 100 50 218 218 173 136 119 212 204 258 228 247 237 147 142 152 137 137 127 128 134 107 91 86 81 11 14 17 20 3 4 350 300 250 200 150 4.7 3.8

More information

untitled

untitled COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5

More information

合併後の交付税について

合併後の交付税について (1) (2) 1 0.9 0.7 0.5 0.3 0.1 2 3 (1) (a), 4 (b) (a), (c) (a) 0.9 0.7 0.5 0.3 0.1 (b) (d),(e) (f) (g) (h) (a) (i) (g) (h) (j) (i) 5 (2) 6 (3) (A) (B) (A)+(B) n 1,000 1,000 2,000 n+1 970 970 1,940 3.0%

More information

170920_BioXCell社カタログ改訂2【9校】.indd

170920_BioXCell社カタログ改訂2【9校】.indd BULK ANTIBODIES for in vivo RESEARCH Bio X Cell in vivo InVivoPlus 0.001 EU/ug 95 5 FACS ELISA 4-1BB CD137 Mouse LOB12.3 Rat IgG1 4-1BB activation BP0169 CD3 ε Mouse 145-2C11 Armenian Hamster IgG1 DP,

More information

B000 B913 B913 S000 S500 L500 L913 B400 B913 B933 S320 L000 L913 492 498 P 38 5 P591 P595 P596 900 911 913 913 913 913 914 916 930 493 498 P 528 P594 P596 P597 910 913 913 913 913 913 914 918 700 723 746

More information

MG

MG 130108 07 チ 010403 0209 0502 0404 0102ィェ02ィーィィ ツ0209ィコィィ02 ィャ0201ィ ィェィィ04ィャ04 000608ィャィィ080609ィ ィェィィ07 0905ィョ01060906ィヲ ィョ05ィィィーィコィィ ィィ ィコ0608ィーィィ0209ィ 060800ィ ィェィ 000005ィィ ィェ0202 00.08. 07 ツ 080203 0102

More information

051

051 June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT June THE JAPANESE JOURNAL OF ANTIBIOTICS

More information

AllPrep DNA/RNA Micro プロトコールとトラブルシューティング ( /2008)

AllPrep DNA/RNA Micro プロトコールとトラブルシューティング ( /2008) July 2007 AllPrep DNA/RNA Micro DNA RNA 5 x 10 5 5 mg Sample & Assay Technologies DNA RNA 3 DNA RNA 11 DNA RNA 19 24 2 AllPrep DNA/RNA Micro 07/2007 DNA RNA RNA AllPrep DNA Spin Column DNA RNeasy MinElute

More information

Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e

Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e 7 -a 7 -a February 4, 2007 1. 2. 3. 4. 1. 2. 3. 1 Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e z

More information

取扱説明書 [F-02F]

取扱説明書 [F-02F] F-02F 4. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d a b cd 9 e a b c d e 20 2 22 ab a b 23 a b 24 c d e 25 26 o a b c p q r s t u v w d h i j k l e f g d m n a b c d e f g h i j k l m n x 27 o

More information

CVMに基づくNi-Al合金の

CVMに基づくNi-Al合金の CV N-A (-' by T.Koyama ennard-jones fcc α, β, γ, δ β α γ δ = or α, β. γ, δ α β γ ( αβγ w = = k k k ( αβγ w = ( αβγ ( αβγ w = w = ( αβγ w = ( αβγ w = ( αβγ w = ( αβγ w = ( αβγ w = ( βγδ w = = k k k ( αγδ

More information

cit_7.vp

cit_7.vp 132007 000606020902010608 0606ィャ49, 017 06030408030608 0601030006 チ030508020102 0601050709050608 010209020001020102 0002050108 07 08040405 05 03020002020507 0003050301090600010409 050600020902000409 080903060208

More information

SIRIUS_CS3*.indd

SIRIUS_CS3*.indd SIRIUS Innovations SIRIUS SIRIUS Answers for industry. SIRIUS SIRIUS S00 S0 SIRIUS SIRIUS ZX0-ORAZ-0AB0 7.5kW 6 S00 7 8 7.5kW 9 S00 0 8.5kW S0 8.5kW S0 5 6 7 IO-Link AS-InterfaceRT 8 8US 5 6 SIRIUS SIRIUS

More information

arakidonsan.rtf

arakidonsan.rtf DHA (ARA) ARA DHA 50 DHA 20 DHA( ) γ 300 mg 170 mg 150 mg 78 mg 57 mg 3,200 mg 2,300 mg 1,700 mg 1,700 mg 1,700 mg β- E FAO DHA( ARA) DHA 2ARA 1 DHA 70mg 100g 35mg 100g 6 6 63 EPA DHA 63 6 EHA DHA 50 WEB

More information

,829 [ 633 ] , EU 48 OECD OECD

,829 [ 633 ] , EU 48 OECD OECD 2009 7 24 540-0011 http://www.osaka.doyu.jp 1 2010 22 2,829 [ 633 ] 33 1 2009 4 1 40,942 1990 2 38 86 2000 EU 48 OECD 2004 6 OECD 21 2 21 2009 4 1 499 393 13.9 0 4 915 32.3 780 27.6 500 999 123 4.3 5 9

More information

0120

0120 文部科学省 科学研究費補助金 新学術領域研究 修飾シグナル病 第二回公開シンポジウム 修飾シグナル病 学術領域の新展開 抄録集 プログラム 2012年1月28日 土 13:00 17:30 東京大学医科学研究所 1号館1F講堂 領域代表者 井上純一郎 2 2012 1 28 13:00-13:10 13:10-15:10 1...2...4...6...8 15:30-17:20 2...10...12...14

More information

137

137 136 137 16 12 16 17 3 18 138 8 125 144 269 9 125 144 269 10 125 144 269 11 125 144 269 12 125 143 268 13 124 146 270 14 124 147 271 15 124 149 273 16 124 149 273 17 124 152 276 4 1 3 3 3 3 3 3 8 2,641

More information

1 A : : 00 Rho G DOCK Rho G Rac1 DOCK GFP FRET Förster resonance energy transfer : Apico - Basal 3 FRET G 3 Rac1 Ras 1 A : :

1 A : : 00 Rho G DOCK Rho G Rac1 DOCK GFP FRET Förster resonance energy transfer : Apico - Basal 3 FRET G 3 Rac1 Ras 1 A : : 1 A - 1 9 : 00 9 : 40 SLE RA SLE RA 1 1 SLE RA SLE SLE 1,2,4,11,17 1 synteny SLE SLE 1 SLE RA SLE RA SLE RA 1 A - 2 9 : 40 10 : 20 L L B L26 Ishii Y, et al. Clin Exp Immunol. 1984. L26 CD20 L L22 B L22

More information

【生】④廣瀬政雄先生【本文】/【生】④廣瀬政雄先生【本文】

【生】④廣瀬政雄先生【本文】/【生】④廣瀬政雄先生【本文】 YOMIURI ONLINE MSN Jp Yahoo!Japan HIV RS MR MR Statens Serum human immunodefficiency virus HIV HIV HIV UNAIDS WHO HIV HIV HIV NGO WHO CDC CDC RS RS E T A E T ATL Adult T cell leukemia ATL A A O O O O O

More information

&

& & & & c & B & c & & aa c c a a nk a a & a aa aaa & A A A A & 7 & & c og og & c c k g a og ok c c & 7 7 n & aa & & & & & & & & & & & g & & a a & & 171 1 & 1 7 1 1 6 de 666 66 6 7 6 f 6 & & c & 1 1 1 1 1

More information

B

B B YES NO 5 7 6 1 4 3 2 BB BB BB AA AA BB 510J B B A 510J B A A A A A A 510J B A 510J B A A A A A 510J M = σ Z Z = M σ AAA π T T = a ZP ZP = a AAA π B M + M 2 +T 2 M T Me = = 1 + 1 + 2 2 M σ Te = M 2 +T

More information

10 2 2 10 6.5 78 1 65 / 30 / - 2 -

10 2 2 10 6.5 78 1 65 / 30 / - 2 - - 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9

More information

Our previous researches have demonstrated the enhanced angiogenesis and ectopic bone formation by a single delivery system of stromal cell-derived fac

Our previous researches have demonstrated the enhanced angiogenesis and ectopic bone formation by a single delivery system of stromal cell-derived fac Our previous researches have demonstrated the enhanced angiogenesis and ectopic bone formation by a single delivery system of stromal cell-derived factor-1 (SDF-1) and bone morphogenetic protein-2 (BMP-2)

More information

001-007 扉・口絵・目次

001-007 扉・口絵・目次 1 6 6 7 1 a a a a 2 a a a 3 4 5 a 6 7 8 9 10 a 11 a a a 12 13 14 15 a 16 17 18 19 20 21 22 23 24 b b 25 b 26 27 aa 28 r r 29 a s d f 30 b b 31 32 33 1 34 35 36 37 38 6 39 6 40 41 42 43 44 45 7 47 48

More information

IF_SUPRECUR_N29

IF_SUPRECUR_N29 ! @ # $ % ^ & * ( ) _ + )# ! a s d a s d f g h a s d @ a s d a s # a s d f g h j $ a s d f g h a s d % a s a a s a s a s d f g ^ a s a s a s & a s d f a s d f g h a s d f g a s d f g a s d a s d * s

More information

H28.4 / 11 28 7 1 28 28 1 27 29 30 4 1 29 5 5 2 2 1 2 2 28 3 1 28 http://www.city.saitama.jp/005/001/018/003/p036471.html 2 28 7 11 28 8 31 3 CD DVD 4 4 5 7 11 8 31 9 1 9 30 10 1 10 31 11 1 11

More information